Malignant syndrome in Parkinson's disease: concept and review of the literature (Q34533456)

2 August 2017

1 reference

title

Malignant syndrome in Parkinson's disease: concept and review of the literature (English)

1 reference

malignant syndrome in Parkinson's disease

2 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

31 December 2023

1

Yoshikuni Mizuno

1 reference

2 August 2017

Hideki Takubo

2

1 reference

2 August 2017

Eiiji Mizuta

3

1 reference

2 August 2017

Sadako Kuno

4

1 reference

2 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12735909

31 December 2023

publication date

1 April 2003

1 reference

full work available at URL

2 August 2017

https://api.elsevier.com/content/article/PII:S1353802002001256?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

https://api.elsevier.com/content/article/PII:S1353802002001256?httpAccept=text/plain

31 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

Parkinsonism and Related Disorders

31 December 2023

published in

1 reference

2 August 2017

volume

9 Suppl 1

1 reference

2 August 2017

page(s)

S3-9

1 reference

Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome: review and analysis of 115 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Fatal hyperpyrexia after withdrawal of levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic Malignant Syndrome in Parkinson's Disease After Withdrawal or Alteration of Dopaminergic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Malignant hyperthermia and excitation-contraction coupling

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Molecular mechanisms of regulation of the activity of sarcoplasmic reticulum Ca-release channels (ryanodine receptors), muscle fatigue, and Severin's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Aetiology of malignant hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Sulpiride increases and dopamine decreases intracranial temperature in rats when injected in the lateral hypothalamus: an animal model for the neuroleptic malignant syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Hypothalamic pathology in the neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Successful Treatment of Levodopa-induced Neuroleptic Malignant Sydrome(NMS) and Disseminated Intravascular Coagulation(DIC) in a Patient with Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome in striatonigral degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome in parkinsonian patients: risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

"On-off"-induced lethal hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Assessment of neuroleptic-like properties of progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Successful treatment of an episode of malignant hyperthermia using a large dose of dantrolene

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

[Malignant syndrome associated with disseminated intravascular coagulation and a high level of amylase in serum, followed by diabetic coma in an elderly patient with Parkinson's disease during L-dopa therapy]

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic malignant syndrome: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Genetics and pathogenesis of malignant hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Ryanodine receptor mutations in malignant hyperthermia and central core disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2802%2900125-6

7 January 2021

Neuroleptic Malignant Syndrome-like State Following a Withdrawal of Antiparkinsonian Drugs

1

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

Functional hyperthermia due to central dopaminergic impairment

31 December 2023

10

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

Neuroleptic malignant-like syndrome following levodopa withdrawal

31 December 2023

11

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

Neuroleptic malignant syndrome complicating levodopa withdrawal

31 December 2023

13

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease

31 December 2023

24

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

Malignant syndrome in multiple system atrophy

31 December 2023

28

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation

31 December 2023

40

1 reference

https://api.crossref.org/works/10.1016/S1353-8020(02)00125-6

31 December 2023

Identifiers

1 reference

2 August 2017

1 reference